Labroots

The Importance of Preclinical Safety Assessments in Drug Development

Preclinical safety assessments are absolutely vital in drug development. Before a new drug can be tested in humans, it must undergo rigorous evaluation to ensure its safety and efficacy. Preclinical ...
GEN

Catalent to Acquire Juniper, Adding Early Drug Development Capabilities

Catalent said today it has agreed to acquire Juniper Pharmaceuticals for $133 million, in a deal that adds a U.K. center of excellence for early drug development to similar centers that the buyer ...
Business Wire

Enveric Biosciences Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the ...
FiercePharma

Characterizing Drug Substance Properties Early Can Optimize Drug Product Formulation

Early on, the drug substance (DS) manufacturer will provide a wealth of preliminary characterization data. And if the drug is active in early nonclinical and preclinical testing, a larger quantity of ...
Seeking Alpha

Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development

Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven ...
Nasdaq

Virpax Reports Favorable Preclinical Safety Data for Envelta™ for the Treatment of Acute and Chronic Pain

BERWYN, Pa.--(BUSINESS WIRE)-- Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management, as ...
News Medical

ATCC announces award from national institute of allergy and infectious diseases to support its preclinical services for biopharmaceutical product development

ATCC, the world’s premier biological materials management and standards organization, today announced that it has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract 75N93023D00009 ...
FiercePharma

Bend Research Announces Extension of Drug-Discovery Enablement and Development Services Agreement With Bristol-Myers Squibb

BEND, Ore., Oct. 18 /PRNewswire/ -- Bend Research Inc. (www.bendres.com), a leading independent technology-based drug-formulation development and manufacturing organization, announced today it has ...
Business Wire

Curia to Acquire Integrity Bio, Expanding Biologic Formulation and Fill-Finish Capabilities

ALBANY, N.Y.--(BUSINESS WIRE)--Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has entered into a definitive agreement to acquire ...
PharmTech

FAQ: Key AI Applications in Drug Development

AI and ML predict solubilization technologies, optimizing drug-excipient interactions and reducing trial-and-error in formulation development. Digital twins, trained ...

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from ...